antilymphocyte serum — Competitive Intelligence Brief

antilymphocyte serum (antilymphocyte serum) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressant. Area: Immunology.

phase 3 Immunosuppressant Lymphocytes Immunology Small molecule

Target snapshot

antilymphocyte serum (antilymphocyte serum) — National Heart, Lung, and Blood Institute (NHLBI). Antilymphocyte serum works by suppressing the immune system to prevent organ rejection in transplant patients.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
antilymphocyte serum TARGET	antilymphocyte serum	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Immunosuppressant	Lymphocytes
Mabthera	Rituximab-Pvvr	Roche	marketed	Monoclonal antibody	CD20 antigen on pre-B and mature B-lymphocytes	1997-01-01
Individual ATG	Individual ATG	The First Affiliated Hospital of Soochow University	marketed	Polyclonal antithymocyte globulin (immunosuppressant)	T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens)
ATG+mycophénolate mofétil+tacrolimus	ATG+mycophénolate mofétil+tacrolimus	University Hospital, Toulouse	marketed	Immunosuppressive combination therapy	T lymphocytes (ATG); IMPDH (mycophenolate mofetil); calcineurin (tacrolimus)
CsA+ATG+Herombopag	CsA+ATG+Herombopag	Peking Union Medical College Hospital	marketed	Immunosuppressive agent + thrombopoietin receptor agonist combination	Calcineurin (CsA); T lymphocytes (ATG); thrombopoietin receptor (eltrombopag)
Mavenclad®	Mavenclad®	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	marketed	Purine nucleoside analog; immunosuppressant	Deoxyadenosine kinase; DNA synthesis and repair pathways in lymphocytes
Cy-ATG	Cy-ATG	Cooperative Study Group A for Hematology	phase 3	Immunosuppressive agent / Polyclonal antibody	T lymphocytes (CD2, CD3, CD4, CD8 antigens)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressant class)

1. Assistance Publique Hopitaux De Marseille · 1 drug in this class
2. Centre Hospitalier Universitaire, Amiens · 1 drug in this class
3. Hospices Civils de Lyon · 1 drug in this class
4. I.M. Sechenov First Moscow State Medical University · 1 drug in this class
5. Kenya Medical Research Institute · 1 drug in this class
6. Memorial Sloan Kettering Cancer Center · 1 drug in this class
7. National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. RWTH Aachen University · 1 drug in this class
10. Samsung Medical Center · 1 drug in this class